Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million
07:48am, Monday, 19'th May 2025
Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe's assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup.
Regeneron to buy bankrupt genetic testing firm 23andMe for $256 million
07:43am, Monday, 19'th May 2025
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said on Monday.
Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe's customer data; stands ready to work with independent, cour
Adam Kovalčík , 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world's largest pre-college STEM competit
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
02:02pm, Thursday, 15'th May 2025
Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market
Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
07:54am, Thursday, 15'th May 2025
As of mid-May 2025, the S&P 500 has turned positive year-to-date (YTD) for the first time in many weeks. Stocks across multiple sectors have broadly recovered from the jolt of tariff news and other vo
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
09:55am, Wednesday, 14'th May 2025
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.
Regeneron Pharmaceuticals, Inc. (REGN) BofA Securities 2025 Healthcare Conference (Transcript)
03:43pm, Tuesday, 13'th May 2025
Regeneron Pharmaceuticals, Inc.
Best Biotech Stocks to Buy in 2025
08:10am, Tuesday, 13'th May 2025
The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector.
Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down
12:35pm, Monday, 12'th May 2025
Regeneron Pharmaceuticals gets a buy rating today, agreeing with the Wall St consensus. Impressive are its drug discovery pipeline across several clinical segments, profit margins, and low Debt/Equity
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
12:30pm, Monday, 12'th May 2025
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t
Landmark Science Makes RWE Services for Biopharma Industry a Boutique Experience
10:04am, Friday, 02'nd May 2025
LOS ANGELES, May 2, 2025 /PRNewswire/ -- Landmark Science, a premier provider of real-world evidence (RWE) solutions, is redefining industry standards with its white-glove, high-touch approach to evid
18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies 18 presentations across five cancer types include new insights on the
24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma
Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides
02:52pm, Tuesday, 29'th Apr 2025
On Tuesday, Regeneron Pharmaceuticals Inc REGN reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82.
